

MedAnnex Attends the American College of Rheumatology Conference.

San Francisco, California, 6 - 11th November 2015.

MedAnnex joined 16,000 attendees from around the world at the annual meeting of the American College of Rheumatology (ACR) in San Francisco.

The ACR conference is the premier scientific meeting for those researching and delivering rheumatologic care, including physicians, health professionals and industry partners from over 100 countries.

Showcasing cutting edge developments in the science of rheumatology, as well as the prevention, diagnosis, and treatment of rheumatic diseases and comorbid conditions, the conference represents a great opportunity to share ideas and form links with other innovators in the field.

About MedAnnex

MedAnnex Ltd, based in Scotland, is a dynamic biotechnology company developing new treatments for people with autoimmune diseases. The company's lead product - Annexuzlimab® - is a humanised monoclonal antibody which, in extensive non-clinical testing, has shown significant activity in rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus.